Inloggad som:

CheckMate 73L

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

CheckMate 73L
CheckMate 73L
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, LocallyA Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, LocallyA Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, LocallyA Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
PLACEHOLDER
Studie på kurativ lungcancer i stadium III som får radiokemoterapi med tillägg av Ipilimumab/Nivolumab samt standardunderhållsbehandling med Durvalumab eller Ipi/Nivo i olika kombinationer
Mer information om studien för vårdgivare
Behandling
Fas 3
Ej tillämpbar
Företag

Studien ändrades senast av: Birgitta Nässén (2020-02-05)

Tillbaka till listan